Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Xarelto
Pharma
J&J, Bayer's Xarelto proves its worth across PAD patients
In the analyses, Xarelto was shown to help "fragile" peripheral artery disease (PAD) patients and those with comorbid coronary artery diseases (CAD).
Zoey Becker
Nov 14, 2023 11:33am
ICER weighs in on Eliquis, Xarelto price negotiations at CMS
Oct 2, 2023 2:42pm
Bayer's new CEO Bill Anderson weighs structural change
Aug 8, 2023 11:15am
J&J joins the roster of drugmakers to file suit against IRA
Jul 18, 2023 6:15pm
Bayer's potential blockbusters Nubeqa, Kerendia thrive in Q1
May 11, 2023 11:16am
PAD patients benefit from aspirin plus Bayer and J&J's Xarelto
Mar 6, 2023 7:53am